Press release
Geron Corporation Reports Greater Than 90% Enrollment in IMerge Phase 3 and Expected Top-Line Results Accelerated to First Quarter of 2023
Completion of Enrollment in IMerge Phase 3 Expected in the Fourth Quarter of 2021 Investor Day Planned for November Second Quarter and Year to Date 2021
About this update from Geron Corporation
[{"type":"text","content":"\nCompletion of Enrollment in IMerge Phase 3 Expected in the Fourth Quarter of 2021\n\nInvestor Day Planned for November \n\nSecond Quarter and Year to Date 2021 Financial Results Also Reported\n\nConference Call Scheduled for 4:30 p.m. ET Today\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported updates on the IMerge Phase 3 trial in lower risk MDS and financial results for the second quarter ended June 30, 2021. The Company will host a conference call today at 4:30 p.m. ET to discuss these updates and current events. As of June 30, 2021, the Company had $239.1 million in cash and marketable securities. These financial resources, combined with expected future non-dilutive funding under the current debt facility, are expected to fund operations through the end of the first quarter of 2023.\n\n“We are pleased with the achievement of 91% of the planned enrollment in IMerge Phase 3 and expect the trial to be fully enrolled in the fourth quarter of 2021. In addition, the expected timing for top-line results in IMerge Phase 3 has been accelerated by three months to the first quarter of 2023,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “By confirming the results from IMerge Phase 2 in the current IMerge Phase 3, including the depth, breadth and durability of transfusion independence, as well as the potential for disease modification, we expect imetelstat to be a highly differentiated product in lower risk MDS in comparison to drugs currently approved or in development today. We look forward to bringing this innovative and important drug to lower risk MDS patients, for whom there remain limited treatment options.”\n\nPhase 3 Clinical Development\n\nOngoing IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes (LR MDS)\n\nAs of August 12, 2021, the Company had achieved 91% of the planned enrollment in IMerge Phase 3. The Company expects the trial to be fully enrolled in the fourth quarter of 2021. In July 2021, a regularly scheduled Independent Data Monitoring Committee (IDMC) meeting was held, and the IDMC recommended that the trial continue without modification.\n\nThe significantly longer enrollment period caused by the COVID-19 pandemic has enabled a longer follow-up period than previously projected. As a...